Our study results implicate that the targeted blocking of ERCC-1, MRP-2, XIAP, and, therefore, activating the mitochondrial apoptotic pathway could be feasible therapeutic strategies for effectively alleviating platinum resistance in HOXB9-overexpressing ovarian mucinous carcinoma in clinical practice. This evidence concerns the gene ERCC1 and ovarian mucinous adenocarcinoma.